Bayer AG manufactures innovative APIs and pharmaceutical formulations across diverse therapeutic areas.

Reset all filters
01 21Xarelto
02 1XareltoTM
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2020 Revenue in Millions : 5,461
2019 Revenue in Millions : 4,991
Growth (%) : 9
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2021 Revenue in Millions : 5,213
2020 Revenue in Millions : 5,461
Growth (%) : 5
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2022 Revenue in Millions : 4,742
2021 Revenue in Millions : 5,213
Growth (%) : -9
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2023 Revenue in Millions : 4,428
2022 Revenue in Millions : 4,742
Growth (%) : -10
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2024 Revenue in Millions : 3,665
2023 Revenue in Millions : 4,428
Growth (%) : -17
Main Therapeutic Indication : Anticoagulants
Currency : USD
2015 Revenue in Millions : 1,847
2014 Revenue in Millions : 2,477
Growth (%) : 34%
Main Therapeutic Indication : Anticoagulants
Currency : USD
2014 Revenue in Millions : 76.90%
2013 Revenue in Millions :
Growth (%) :
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2017 Revenue in Millions : 4,090
2016 Revenue in Millions : 3,631
Growth (%) : 13
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2018 Revenue in Millions : 4,103
2017 Revenue in Millions : 3,727
Growth (%) : 10%
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2016 Revenue in Millions : 3,104
2015 Revenue in Millions : 2,387
Growth (%) : 30



